Premium Nahrungsergänzungsmittel | artgerecht

Ischemia Modified Albumin (IMA) Explained

Ischemia modified albumin (IMA) is a blood biomarker that forms during oxygen deprivation in cardiac tissue and is used for the early diagnosis of heart attack.

Regular tips about health Regular tips about health

Things worth knowing about "Ischemia modified albumin"

Ischemia modified albumin (IMA) is a blood biomarker that forms during oxygen deprivation in cardiac tissue and is used for the early diagnosis of heart attack.

What is Ischemia Modified Albumin?

Ischemia modified albumin (IMA) is an altered form of the blood protein albumin that is produced when heart tissue or other tissues experience ischemia – a state of acute oxygen deprivation. During ischemia, the N-terminal amino acids of albumin undergo chemical modification, significantly reducing the protein's ability to bind cobalt ions. This change can be detected in the blood and serves as an early indicator of a possible heart attack or other ischemic events.

Importance as a Biomarker

IMA is considered one of the earliest detectable cardiac biomarkers. While classic cardiac markers such as troponin or CK-MB only rise after myocardial damage has occurred, IMA levels in the blood increase within minutes of the onset of ischemia – before any irreversible tissue damage takes place. This makes IMA particularly valuable for the early detection of acute coronary syndrome (ACS).

Formation and Mechanism of Action

Albumin is the most abundant protein in human blood plasma. At its N-terminal end (the beginning of the protein structure), there is a binding region for transition metals such as cobalt, copper, and nickel. Under ischemic conditions – i.e., during oxygen deprivation – oxidative stress, acidosis (tissue acidification), and the release of free radicals chemically modify this binding region. The resulting IMA binds significantly less cobalt than normal albumin, and this difference forms the basis of the diagnostic test.

Diagnosis: The Albumin Cobalt Binding (ACB) Test

IMA is detected using the albumin cobalt binding (ACB) test. A defined amount of cobalt chloride is added to the patient's blood plasma. With normal albumin, cobalt binds to the N-terminus. With IMA, more free cobalt remains unbound in the plasma. The amount of unbound cobalt is measured photometrically and reflects the IMA content in the blood. Elevated IMA values indicate active myocardial ischemia.

Reference Values

The threshold for elevated IMA is typically around 85 kU/L (cobalt units per liter), though this may vary slightly depending on the laboratory and testing method. Values above this threshold are considered clinically relevant and require further diagnostic evaluation.

Clinical Application

IMA is used primarily in the emergency department for patients presenting with chest pain to help rule out or confirm acute coronary syndrome at an early stage. Since IMA alone does not have sufficient specificity, it is always used in combination with other tests:

Troponin I or T (cardiac necrosis marker)
ECG (electrocardiogram to assess cardiac activity)
CK-MB (creatine kinase-MB fraction)

Combining these tests significantly increases diagnostic accuracy. Studies show that combining IMA with troponin and ECG can achieve a negative predictive accuracy of over 95% for ruling out acute myocardial infarction.

Other Causes of Elevated IMA Levels

IMA is not heart-specific. Elevated IMA levels can also occur in other conditions associated with ischemia or oxidative stress:

Stroke (cerebral ischemia)
Peripheral arterial disease (PAD)
Intestinal ischemia
Severe infections and sepsis
Liver disease
Advanced cancer
Intense physical stress

This lack of organ specificity is the main reason why IMA must always be interpreted in the clinical context and in combination with other markers.

Advantages and Limitations

Advantages

Early rise within 6–10 minutes of ischemia onset
Normalizes within 6–12 hours – providing a clear diagnostic time window
Simple to perform and cost-effective
Useful for early exclusion of ACS in the emergency setting

Limitations

Low cardiac specificity – influenced by many factors
Albumin levels affect test results (e.g., in liver disease)
Not a replacement for troponin as the gold standard of cardiac diagnostics
Limited data in certain patient populations

References

Bar-Or D. et al. - An analog of the albumin cobalt binding test for the detection of myocardial ischemia: a point-of-care marker for the early detection of acute coronary syndrome. - Point of Care, 2008.
Bhagavan NV et al. - Ischemia-modified albumin: correlation with myocardial ischemia in the emergency department. - Clinical Chemistry, 2003.
Apple FS et al. - Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. - Clinical Chemistry, 2005.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category